Latest news with #ARKG
Yahoo
4 days ago
- Business
- Yahoo
Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)
In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to overlook some of the most transformative developments in the life sciences. Cathie Wood, CEO of ARK Invest and known for her bold bets on disruptive innovation, has her sights set on Illumina (ILMN), a company that connects science and technology. On July 22, Wood's ARK's Genomic Revolution ETF (ARKG) bought 31,265 shares of Illumina, amounting to nearly $2.98 million, bringing the total investment in the company to $32 million. It is the ETF's 15th largest holding, comprising 2.8% of the overall portfolio. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Let's find out if investors should follow Wood's lead and buy Illumina stock here. A High-Conviction Bet on the Future of Medicine Valued at $16.6 billion, Illumina is a biotechnology company that specializes in genome sequencing, or the process of reading and analyzing DNA. It manufactures machines (sequencers), software, and chemical kits that are used to decode the genetic material (DNA) of humans, animals, plants, and bacteria. Illumina's technology is used in hospitals and clinics, by cancer researchers, pharmaceutical companies, agricultural scientists, academics, and research institutions, among others. Some of its products include the NovaSeq X Series, iScan System, iSeq 100 System, Illumina DNA Prep, Illumina Stranded mRNA Prep, and many others. Illumina's stock price has dropped significantly since its 2021 highs, falling from above $500 to around the $100-$120 range by mid-2025. Much of this decline can be attributed to a series of self-inflicted wounds, most notably its controversial acquisition of cancer detection company Grail. However, with the Grail divestment in 2024 and a new CEO, Jacob Thaysen, in charge, Illumina appears to be refocusing on its core business of making genome sequencing cheaper, faster, and more accessible. Why the Timing Matters Now Wood is known for buying when volatility is high, particularly when she believes the market has overcorrected due to near-term concerns. Following the Grail divestment, leadership change, and a multi-quarter slump in revenue growth, investor sentiment is bearish on Illumina stock, explaining the nearly 20% drop year-to-date. However, Wood saw this as an opportunity to stock up on this rising genomic star. Illumina's financial performance appears to be stabilizing. For a growth investor like Wood, who prefers to overlook short-term earnings volatility in favor of long-term potential, these improvements are a welcome sign that the company is on the right track. In the first quarter, while revenue growth dipped slightly by 1.4%, the company improved its margins and reduced unnecessary expenses. Illumina exceeded revenue expectations and reaffirmed full-year guidance. Adjusted gross margins increased to 67.4% as a result of improved manufacturing efficiency and lower R&D costs. Adjusted earnings per share fell to $0.97 from $0.98 in the prior year's quarter. Remaining performance obligations (RPO) totaled $891 million, of which Illumina expects to generate 83% in revenue over the next year. With a reasonable debt-equity ratio of 0.63x, Illumina's balance sheet is stable. The company also generated a positive free cash flow of $208 million during the quarter. Illumina will report its second-quarter earnings on July 31. Analysts expect revenue of $1.05 billion on earnings per share of $1.01. Analysts predict a 3% drop in revenue for the full year but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026. Another factor that may have influenced ARK's decision to increase its stake in Illumina is valuation. The stock is currently trading at 22 times forward earnings for 2026 and three times forward sales. Illumina has the world's largest genomics dataset, giving the company a competitive advantage. Many of Illumina's future revenue streams, including large-scale population sequencing contracts and new clinical applications in oncology and rare diseases, are not fully priced into current projections. This reasonable valuation represents a buying opportunity for a growth stock with excellent long-term prospects. What Is Wall Street Saying About Illumina Stock? Overall, the consensus on Illumina stock is a 'Moderate Buy.' Of the 22 analysts covering the stock, nine recommend a 'Strong Buy,' one suggests a 'Moderate Buy,' nine rate it a 'Hold,' one says it is a 'Moderate Sell,' and two have given it a 'Strong Sell' rating. The stock is trading close to its average target price of $106.83. However, the high price estimate of $185 suggests a rally of over 76.8% from current levels. The Key Takeaway Wood's stake in Illumina is a calculated investment based on extensive research, long-term vision, and a firm belief in the power of genomics to transform healthcare. Now, with a lower cost structure, a clear path back to profit growth, and exciting new products on the market, Illumina is poised for a turnaround. For investors with patience and a long horizon, Illumina stock represents a one-of-a-kind opportunity to invest in genomic infrastructure. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
10-07-2025
- Business
- Yahoo
Cathie Wood's ARK Loads Up on Tempus AI, Cuts Roku and Block
July 10 - Cathie Wood's ARK Invest purchased 150,563 shares of Tempus AI (NASDAQ:TEM), worth about $8.8 million, according to a Wednesday regulatory filing with the SEC. The bulk of the buy flowed through the ARK Innovation ETF (ARKK), with the remainder acquired via the ARK Genomic Revolution ETF (ARKG). Tempus AI applies artificial intelligence to clinical decision?making, a focus area for Wood's disruptive?tech strategy. Warning! GuruFocus has detected 5 Warning Signs with TEM. At the same time, ARK trimmed its position in Roku (NASDAQ:ROKU), selling 50,823 shares, roughly $4.5 million, also via ARKK. This marks a second consecutive day of reductions in the streaming platform stock. The fund likewise pared back exposure to Block, offloading 56,503 shares worth about $6.5 million, as part of a broader pullback from fintech names. These moves illustrate ARK's ongoing pivot toward AI health plays and away from streaming and payments. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Business
- Yahoo
Cathie Wood shells out $13.9 million for one high-stakes biotech stock
Cathie Wood shells out $13.9 million for one high-stakes biotech stock originally appeared on TheStreet. Amid all the noise over tariffs and rate-cut chatter, the smartest move is often to follow investors who've done it before. 💵💰💰💵 Love her or hate her, Cathie Wood is a true maverick who's made a name finding tomorrow's big disruptors long before anyone else. Now, with a fresh swing at a major biotech stock, it says a lot about where she thinks the next big win will come from. Cathie Wood's love affair with biotech stocks has been part of ARK's DNA since day one. Long before CRISPR became a Wall Street buzzword, Wood's team has been busy, scooping up shares in early-stage gene-editing names. Her Genomic Revolution ETF, ARKG, was one of ARK's first thematic funds, which made a splash by loading up on companies like Editas Medicine and Intellia Therapeutics. The idea was clear: Programmable gene-editing tools could effectively flip medicine from symptom treatment to real cures. That early leap paid off 2019 and 2020, ARKG posted massive gains, led by positive trial results and big-name pharma partnerships, while broader markets were stuck in neutral. Wood has been consistent in backing her biotech picks, regardless of bad trial news or cash crunches. For her, the appeal of gene editing has more to do with rewriting what health care looks like. She sees CRISPR and next-gen editing tools as critical tools in curing diseases outright, cutting treatment costs, while giving patients their lives back. Such a strategy comes with its fair share of risk, but Wood spreads that risk across multiple platforms. For those who back game-changing science, her biotech playbook is clear and effective at spotting revolutionary picks that typically stun Mr. Market. Cathie Wood kicked off what's been a choppy week with a classic ARK move, in loading big on a key biotech stock while locking in gains elsewhere. On Monday, ARK Invest scooped up 659,000 shares of Beam Therapeutics () , splitting the buy between Wood's flagship ARK Innovation ETF and the ARK Genomic Revolution ETF. More Tech Stock News: Google's quiet AI win spells trouble for Amazon Nvidia-backed stock sends a quiet shockwave through the AI world Veteran Tesla analyst drops 4-word call That comes to more than $13 million in fresh Beam stock, following a relatively smaller buy earlier this week worth roughly $571,000. Beam Therapeutics stands out in the ARK portfolio for good reason. Its robust base-editing technology promises remarkably more precise and safer gene edits than standard of slicing through both strands of DNA, Beam's method efficiently swaps out tiny pieces one at a time, making it a lot safer and more precise. That competitive edge has major stakes. Beam's pipeline includes programs for monogenic disorders including sickle cell and beta-thalassemia, along with multiple readouts lined up for this year. Beam's cash position is another plus for Wood, with the business funded into 2027, easing dilution fears that typically rattle biotech names. Also, a major Pfizer partnership in cardiovascular disease adds new layers to Beam's commercial push, while landing it even more credibility on the stock market. Hence, for Wood, Beam essentially ticks every box. Its powerful disruptive science, tangible milestones, and huge upside potential suggest a long-term winner. It's exactly the kind of swing-for-the-fences bet ARK is famous for and has made many millionaires in the process. On the flip side, Wood's team lightened up on Roblox () , selling 31,416 shares worth roughly $3.25 million of the popular gaming stock as it rebounded. That follows ARK's moves last week, where it sold 26,877 shares of the gaming giant. As always, biotech isn't for the faint-hearted, but for Cathie Wood, Beam is the moonshot that's in position to rewrite Wood shells out $13.9 million for one high-stakes biotech stock first appeared on TheStreet on Jul 8, 2025 This story was originally reported by TheStreet on Jul 8, 2025, where it first appeared.
Yahoo
08-07-2025
- Business
- Yahoo
Cathie Wood shells out $13.9 million for one high-stakes biotech stock
Cathie Wood shells out $13.9 million for one high-stakes biotech stock originally appeared on TheStreet. Amid all the noise over tariffs and rate-cut chatter, the smartest move is often to follow investors who've done it before. 💵💰💰💵 Love her or hate her, Cathie Wood is a true maverick who's made a name finding tomorrow's big disruptors long before anyone else. Now, with a fresh swing at a major biotech stock, it says a lot about where she thinks the next big win will come from. Cathie Wood's love affair with biotech stocks has been part of ARK's DNA since day one. Long before CRISPR became a Wall Street buzzword, Wood's team has been busy, scooping up shares in early-stage gene-editing names. Her Genomic Revolution ETF, ARKG, was one of ARK's first thematic funds, which made a splash by loading up on companies like Editas Medicine and Intellia Therapeutics. The idea was clear: Programmable gene-editing tools could effectively flip medicine from symptom treatment to real cures. That early leap paid off 2019 and 2020, ARKG posted massive gains, led by positive trial results and big-name pharma partnerships, while broader markets were stuck in neutral. Wood has been consistent in backing her biotech picks, regardless of bad trial news or cash crunches. For her, the appeal of gene editing has more to do with rewriting what health care looks like. She sees CRISPR and next-gen editing tools as critical tools in curing diseases outright, cutting treatment costs, while giving patients their lives back. Such a strategy comes with its fair share of risk, but Wood spreads that risk across multiple platforms. For those who back game-changing science, her biotech playbook is clear and effective at spotting revolutionary picks that typically stun Mr. Market. Cathie Wood kicked off what's been a choppy week with a classic ARK move, in loading big on a key biotech stock while locking in gains elsewhere. On Monday, ARK Invest scooped up 659,000 shares of Beam Therapeutics () , splitting the buy between Wood's flagship ARK Innovation ETF and the ARK Genomic Revolution ETF. More Tech Stock News: Google's quiet AI win spells trouble for Amazon Nvidia-backed stock sends a quiet shockwave through the AI world Veteran Tesla analyst drops 4-word call That comes to more than $13 million in fresh Beam stock, following a relatively smaller buy earlier this week worth roughly $571,000. Beam Therapeutics stands out in the ARK portfolio for good reason. Its robust base-editing technology promises remarkably more precise and safer gene edits than standard of slicing through both strands of DNA, Beam's method efficiently swaps out tiny pieces one at a time, making it a lot safer and more precise. That competitive edge has major stakes. Beam's pipeline includes programs for monogenic disorders including sickle cell and beta-thalassemia, along with multiple readouts lined up for this year. Beam's cash position is another plus for Wood, with the business funded into 2027, easing dilution fears that typically rattle biotech names. Also, a major Pfizer partnership in cardiovascular disease adds new layers to Beam's commercial push, while landing it even more credibility on the stock market. Hence, for Wood, Beam essentially ticks every box. Its powerful disruptive science, tangible milestones, and huge upside potential suggest a long-term winner. It's exactly the kind of swing-for-the-fences bet ARK is famous for and has made many millionaires in the process. On the flip side, Wood's team lightened up on Roblox () , selling 31,416 shares worth roughly $3.25 million of the popular gaming stock as it rebounded. That follows ARK's moves last week, where it sold 26,877 shares of the gaming giant. As always, biotech isn't for the faint-hearted, but for Cathie Wood, Beam is the moonshot that's in position to rewrite Wood shells out $13.9 million for one high-stakes biotech stock first appeared on TheStreet on Jul 8, 2025 This story was originally reported by TheStreet on Jul 8, 2025, where it first appeared. Sign in to access your portfolio
Miami Herald
08-07-2025
- Business
- Miami Herald
Cathie Wood shells out $13.9 million for one high-stakes biotech stock
Amid all the noise over tariffs and rate-cut chatter, the smartest move is often to follow investors who've done it before. Don't miss the move: Subscribe to TheStreet's free daily newsletter Love her or hate her, Cathie Wood is a true maverick who's made a name finding tomorrow's big disruptors long before anyone else. Now, with a fresh swing at a major biotech stock, it says a lot about where she thinks the next big win will come from. Cathie Wood's love affair with biotech stocks has been part of ARK's DNA since day one. Long before CRISPR became a Wall Street buzzword, Wood's team has been busy, scooping up shares in early-stage gene-editing names. Her Genomic Revolution ETF, ARKG, was one of ARK's first thematic funds, which made a splash by loading up on companies like Editas Medicine and Intellia Therapeutics. The idea was clear: Programmable gene-editing tools could effectively flip medicine from symptom treatment to real cures. That early leap paid off massively. Related: Cathie Wood makes surprising chip bet as AI battle heats up Between 2019 and 2020, ARKG posted massive gains, led by positive trial results and big-name pharma partnerships, while broader markets were stuck in neutral. Wood has been consistent in backing her biotech picks, regardless of bad trial news or cash crunches. For her, the appeal of gene editing has more to do with rewriting what health care looks like. She sees CRISPR and next-gen editing tools as critical tools in curing diseases outright, cutting treatment costs, while giving patients their lives back. Such a strategy comes with its fair share of risk, but Wood spreads that risk across multiple platforms. For those who back game-changing science, her biotech playbook is clear and effective at spotting revolutionary picks that typically stun Mr. Market. Cathie Wood kicked off what's been a choppy week with a classic ARK move, in loading big on a key biotech stock while locking in gains elsewhere. On Monday, ARK Invest scooped up 659,000 shares of Beam Therapeutics (BEAM) , splitting the buy between Wood's flagship ARK Innovation ETF and the ARK Genomic Revolution ETF. More Tech Stock News: Google's quiet AI win spells trouble for AmazonNvidia-backed stock sends a quiet shockwave through the AI worldVeteran Tesla analyst drops 4-word call That comes to more than $13 million in fresh Beam stock, following a relatively smaller buy earlier this week worth roughly $571,000. Beam Therapeutics stands out in the ARK portfolio for good reason. Its robust base-editing technology promises remarkably more precise and safer gene edits than standard CRISPR. Related: JPMorgan delivers blunt warning on S&P 500 Instead of slicing through both strands of DNA, Beam's method efficiently swaps out tiny pieces one at a time, making it a lot safer and more precise. That competitive edge has major stakes. Beam's pipeline includes programs for monogenic disorders including sickle cell and beta-thalassemia, along with multiple readouts lined up for this year. Beam's cash position is another plus for Wood, with the business funded into 2027, easing dilution fears that typically rattle biotech names. Also, a major Pfizer partnership in cardiovascular disease adds new layers to Beam's commercial push, while landing it even more credibility on the stock market. Hence, for Wood, Beam essentially ticks every box. Its powerful disruptive science, tangible milestones, and huge upside potential suggest a long-term winner. It's exactly the kind of swing-for-the-fences bet ARK is famous for and has made many millionaires in the process. On the flip side, Wood's team lightened up on Roblox (RBLX) , selling 31,416 shares worth roughly $3.25 million of the popular gaming stock as it rebounded. That follows ARK's moves last week, where it sold 26,877 shares of the gaming giant. As always, biotech isn't for the faint-hearted, but for Cathie Wood, Beam is the moonshot that's in position to rewrite history. Related: Amid AI boom, veteran analyst reboots AMD, Supermicro stock price targets The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
